Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer

BACKGROUND: Tamoxifen is the standard endocrine therapy for breast cancers, which require metabolic activation by cytochrome P450 enzymes (CYP). However, the lower and variable concentrations of CYP activity at the tumor remain major bottlenecks for the efficient treatment, causing severe side-effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Kanchan, Hernandez-Meza, Juan M., Rodríguez-Hernández, Ana G., Juarez-Moreno, Karla, Sengar, Prakhar, Vazquez-Duhalt, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819296/
https://www.ncbi.nlm.nih.gov/pubmed/29463260
http://dx.doi.org/10.1186/s12951-018-0345-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819296/
https://www.ncbi.nlm.nih.gov/pubmed/29463260
http://dx.doi.org/10.1186/s12951-018-0345-2

Ejemplares similares